Welcome to our dedicated page for Global X SuperDividend® REIT ETF SEC filings (Ticker: SRET), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Global X SuperDividend® REIT ETF's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Global X SuperDividend® REIT ETF's regulatory disclosures and financial reporting.
Form 4 Overview: Maravai LifeSciences Holdings, Inc. (MRVI) disclosed that director John A. DeFord acquired 89,139 shares of Class A common stock on 16 June 2025.
Transaction details: The shares were granted as restricted stock units (RSUs) under the company’s 2020 Omnibus Incentive Plan at an assigned value of $2.16 per share. These RSUs will vest in full on the earlier of (i) one year from the grant date or (ii) the date of the 2026 annual shareholder meeting.
Post-transaction ownership: Following the award, DeFord’s beneficial ownership rises to 159,185 shares, all held directly.
Implications: A director increasing his stake—albeit via equity compensation—tends to align management and shareholder interests and can be interpreted as a vote of confidence in MRVI’s long-term prospects. Because the grant stems from an incentive plan rather than an open-market purchase, any cash outlay by the insider is not indicated in the filing.
Form 4 Overview: Maravai LifeSciences Holdings, Inc. (MRVI) disclosed that director John A. DeFord acquired 89,139 shares of Class A common stock on 16 June 2025.
Transaction details: The shares were granted as restricted stock units (RSUs) under the company’s 2020 Omnibus Incentive Plan at an assigned value of $2.16 per share. These RSUs will vest in full on the earlier of (i) one year from the grant date or (ii) the date of the 2026 annual shareholder meeting.
Post-transaction ownership: Following the award, DeFord’s beneficial ownership rises to 159,185 shares, all held directly.
Implications: A director increasing his stake—albeit via equity compensation—tends to align management and shareholder interests and can be interpreted as a vote of confidence in MRVI’s long-term prospects. Because the grant stems from an incentive plan rather than an open-market purchase, any cash outlay by the insider is not indicated in the filing.
Form 4 Overview: Maravai LifeSciences Holdings, Inc. (MRVI) disclosed that director John A. DeFord acquired 89,139 shares of Class A common stock on 16 June 2025.
Transaction details: The shares were granted as restricted stock units (RSUs) under the company’s 2020 Omnibus Incentive Plan at an assigned value of $2.16 per share. These RSUs will vest in full on the earlier of (i) one year from the grant date or (ii) the date of the 2026 annual shareholder meeting.
Post-transaction ownership: Following the award, DeFord’s beneficial ownership rises to 159,185 shares, all held directly.
Implications: A director increasing his stake—albeit via equity compensation—tends to align management and shareholder interests and can be interpreted as a vote of confidence in MRVI’s long-term prospects. Because the grant stems from an incentive plan rather than an open-market purchase, any cash outlay by the insider is not indicated in the filing.
Form 4 Overview: Maravai LifeSciences Holdings, Inc. (MRVI) disclosed that director John A. DeFord acquired 89,139 shares of Class A common stock on 16 June 2025.
Transaction details: The shares were granted as restricted stock units (RSUs) under the company’s 2020 Omnibus Incentive Plan at an assigned value of $2.16 per share. These RSUs will vest in full on the earlier of (i) one year from the grant date or (ii) the date of the 2026 annual shareholder meeting.
Post-transaction ownership: Following the award, DeFord’s beneficial ownership rises to 159,185 shares, all held directly.
Implications: A director increasing his stake—albeit via equity compensation—tends to align management and shareholder interests and can be interpreted as a vote of confidence in MRVI’s long-term prospects. Because the grant stems from an incentive plan rather than an open-market purchase, any cash outlay by the insider is not indicated in the filing.
Form 4 Overview: Maravai LifeSciences Holdings, Inc. (MRVI) disclosed that director John A. DeFord acquired 89,139 shares of Class A common stock on 16 June 2025.
Transaction details: The shares were granted as restricted stock units (RSUs) under the company’s 2020 Omnibus Incentive Plan at an assigned value of $2.16 per share. These RSUs will vest in full on the earlier of (i) one year from the grant date or (ii) the date of the 2026 annual shareholder meeting.
Post-transaction ownership: Following the award, DeFord’s beneficial ownership rises to 159,185 shares, all held directly.
Implications: A director increasing his stake—albeit via equity compensation—tends to align management and shareholder interests and can be interpreted as a vote of confidence in MRVI’s long-term prospects. Because the grant stems from an incentive plan rather than an open-market purchase, any cash outlay by the insider is not indicated in the filing.
Form 4 Overview: Maravai LifeSciences Holdings, Inc. (MRVI) disclosed that director John A. DeFord acquired 89,139 shares of Class A common stock on 16 June 2025.
Transaction details: The shares were granted as restricted stock units (RSUs) under the company’s 2020 Omnibus Incentive Plan at an assigned value of $2.16 per share. These RSUs will vest in full on the earlier of (i) one year from the grant date or (ii) the date of the 2026 annual shareholder meeting.
Post-transaction ownership: Following the award, DeFord’s beneficial ownership rises to 159,185 shares, all held directly.
Implications: A director increasing his stake—albeit via equity compensation—tends to align management and shareholder interests and can be interpreted as a vote of confidence in MRVI’s long-term prospects. Because the grant stems from an incentive plan rather than an open-market purchase, any cash outlay by the insider is not indicated in the filing.
Form 4 Overview: Maravai LifeSciences Holdings, Inc. (MRVI) disclosed that director John A. DeFord acquired 89,139 shares of Class A common stock on 16 June 2025.
Transaction details: The shares were granted as restricted stock units (RSUs) under the company’s 2020 Omnibus Incentive Plan at an assigned value of $2.16 per share. These RSUs will vest in full on the earlier of (i) one year from the grant date or (ii) the date of the 2026 annual shareholder meeting.
Post-transaction ownership: Following the award, DeFord’s beneficial ownership rises to 159,185 shares, all held directly.
Implications: A director increasing his stake—albeit via equity compensation—tends to align management and shareholder interests and can be interpreted as a vote of confidence in MRVI’s long-term prospects. Because the grant stems from an incentive plan rather than an open-market purchase, any cash outlay by the insider is not indicated in the filing.
Form 4 Overview: Maravai LifeSciences Holdings, Inc. (MRVI) disclosed that director John A. DeFord acquired 89,139 shares of Class A common stock on 16 June 2025.
Transaction details: The shares were granted as restricted stock units (RSUs) under the company’s 2020 Omnibus Incentive Plan at an assigned value of $2.16 per share. These RSUs will vest in full on the earlier of (i) one year from the grant date or (ii) the date of the 2026 annual shareholder meeting.
Post-transaction ownership: Following the award, DeFord’s beneficial ownership rises to 159,185 shares, all held directly.
Implications: A director increasing his stake—albeit via equity compensation—tends to align management and shareholder interests and can be interpreted as a vote of confidence in MRVI’s long-term prospects. Because the grant stems from an incentive plan rather than an open-market purchase, any cash outlay by the insider is not indicated in the filing.
Form 4 Overview: Maravai LifeSciences Holdings, Inc. (MRVI) disclosed that director John A. DeFord acquired 89,139 shares of Class A common stock on 16 June 2025.
Transaction details: The shares were granted as restricted stock units (RSUs) under the company’s 2020 Omnibus Incentive Plan at an assigned value of $2.16 per share. These RSUs will vest in full on the earlier of (i) one year from the grant date or (ii) the date of the 2026 annual shareholder meeting.
Post-transaction ownership: Following the award, DeFord’s beneficial ownership rises to 159,185 shares, all held directly.
Implications: A director increasing his stake—albeit via equity compensation—tends to align management and shareholder interests and can be interpreted as a vote of confidence in MRVI’s long-term prospects. Because the grant stems from an incentive plan rather than an open-market purchase, any cash outlay by the insider is not indicated in the filing.
Form 4 Overview: Maravai LifeSciences Holdings, Inc. (MRVI) disclosed that director John A. DeFord acquired 89,139 shares of Class A common stock on 16 June 2025.
Transaction details: The shares were granted as restricted stock units (RSUs) under the company’s 2020 Omnibus Incentive Plan at an assigned value of $2.16 per share. These RSUs will vest in full on the earlier of (i) one year from the grant date or (ii) the date of the 2026 annual shareholder meeting.
Post-transaction ownership: Following the award, DeFord’s beneficial ownership rises to 159,185 shares, all held directly.
Implications: A director increasing his stake—albeit via equity compensation—tends to align management and shareholder interests and can be interpreted as a vote of confidence in MRVI’s long-term prospects. Because the grant stems from an incentive plan rather than an open-market purchase, any cash outlay by the insider is not indicated in the filing.
FAQ
What is the current stock price of Global X SuperDividend® REIT ETF (SRET)?
